IPCA Laboratories share news and announcements
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
IPCA Laboratories share news and announcements
771 announcements, routine notices left out, newest first. Page 12 of 16.
Oct 2012
9 Oct · Corporate action
Company has fixed November 02, 2012 as the 'Record Date' for the Members entitlement of interim dividend for the financial year 2012-13 that may be declared at the Board Meeting to be held on October 25, 2012. The dividend if declared shall be paid/ dispatched by November 23, 2012.9 Oct · Board meeting
Inter-alia, to consider following: (1) Unaudited Financial Results for the quarter and half year ended September 30, 2012; and (2) Interim Dividend for the financial year 2012-13.
Sep 2012
Aug 2012
Jul 2012
20 Jul · Updates
Company has received US-FDA approval for its Oral solid dosage formulations manufacturing facility situated at Pharmazone, SEZ Indore, Pithampur, Madhya Pradesh. This approval will enable the Company to commercialize more Oral solid dosage formulations in the US market.16 Jul · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the 1st Quarter ended June 30, 2012.
Jun 2012
27 Jun · Meeting
Annual General Meeting of the Company will be held on July 31, 2012. The Register of Members and Share Transfer Books of the Company will remain closed from July 24, 2012 to July 31, 2012, both days inclusive for the purpose of Annual General Meeting and for the entitlement of final dividend @ Re.1.20 per share (60%) which if sanctioned will be paid on or before August 20, 2012.
May 2012
29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2012 has recommended a final dividend of Rs. 1.20/- per share (60%) for the financial year ended March 31, 2012.17 May · Board meeting
Inter-alia, to consider : (1) The Audited Financial Results for the financial year ended March 31, 2012; and (2) Recommendation of final dividend for the financial year ended March 31, 2012.9 May · Board meeting
Inter-alia, to consider and to take on record : (a) The order passed by the Hon'able High Court of Judicature at Bombay and Hon'able High Court of Gujarat approving the Scheme of Amalgamation of M/s. Tonira Pharma Ltd. with the Company; and (b) To fix the Record Date for the purpose of M/s. Tonira Parma Limited members entitlement of the Company shares in the ratio of 6 (Six) fully paid up equity shares of Rs. 2/- each of the Company for every 100 (One Hundred) fully paid up equity shares of Rs. 10/- each in Tonira Pharma Limited pursuant to the said Company's merger with the Company.
Apr 2012
Jan 2012
31 Jan · Dividend
Board of Directors of the Company at its meeting held on January 31, 2012 has declared 2nd interim dividend of Rs.1/- per share(50%) for the financial year 2011-12.23 Jan · Outcome of meeting
Pursuant to the direction of the Hon`able High Court of Judicature at Bombay , the meetings of the Equity Shareholders and the Unsecured Creditors of the company were held on January 20, 2012. The Equity Shareholders and Unsecured Creditors have passed the resolutions approving the merger of Tonira Pharma Ltd with the Company.20 Jan · Business
At the meeting of the Board of Directors held on January 20, 2012; 1,21,250 fully paid-up equity shares of Rs.2/- each of the Company @ Rs.63 per equity share have been allotted upon exercise of options by allotees to whom options were granted on October 29, 2007 and November 11, 2008 pursuant to Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). Further the Company has informed the Exchange that the equity shares now allotted would rank pari-passu in all respects with the existing paid-up equity share capital of the Company. Also, with this allotment, the paid up equity share capital of the Company is now increased to Rs.25,16,55,310/- divided into 12,58,27,655 fully paid-up equity shares of Rs.2/- each.17 Jan · Corporate action
Company has fixed February 08, 2012 as the 'Record Date' for the purpose of 2nd interim dividend for the financial year 2011-12. Further, the Divided Payment Date will be February 22, 2012.17 Jan · Board meeting
Inter-alia, to consider the following : (1) Unaudited Financial Results for 3rd Quarter and nine months ended December 31, 2011; and (2) 2nd Interim Dividend for the financial year 2011-12.16 Jan · Board meeting
Inter-alia to consider Allotment of equity shares on exercise of optiions under Ipca Laborartories Ltd- Employees Stock Option Scheme - 2006 (ESOS).
Oct 2011
31 Oct · Dividend
Board of Directors of the Company at its meeting held on October 31, 2011 has declared an interim dividend of 50% (Re.1/- per share) for the financial year 2011-12.18 Oct · Corporate action
Company has fix November 07, 2011 as the 'Record Date' for the Members entitlement of interim dividend for the financial year 2011-12 that may be declared at the Board Meeting to be held on October 31, 2011.17 Oct · Board meeting
Inter-alia, to consider following: (1) Unaudited Financial Results for the quarter and half year ended September 30, 2011; and (2) Interim Dividend for the financial year 2011-12.
Sep 2011
19 Sep · Board meeting
Board of Directors of the Company at its meeting held on September 17, 2011, inter alia, have approved amalgamation of Tonira Pharma Limited with the Company with effect from April 01, 2011 (being the appointed date) through a Scheme of Amalgamation. The Scheme envisages an exchange ratio of 6 (Six) equity shares of Rs. 2/- each fully paid-up of Ipca Laboratories Limited for every 100 (One Hundred) equity shares of Rs. 10/- each fully paid-up of Tonira Pharma Limited. The exchange ratio is based on the joint valuation made by M/s. Natvarlal Vepari & Co., Chartered Accountants and M/s. G. M. Kapadia & Co., Chartered Accountants. The proposed scheme of Amalgamation will be subject to all necessary permissions and approvals, as may be required.9 Sep · Board meeting
Inter-alia, to consider the Amalgamation / Merger of Tonira Pharma Limited with the Company.
Aug 2011
9 Aug · Updates
Ipca Laboratories Limited had informed the Exchange regarding a press release dated August 09, 2011 being issued by the Company in connection with acquisition of 100% share capital of Onyx Research Chemicals Ltd. holding Company of Onyx Scientific Ltd. by Company's wholly owned subsidiary Ipca Laboratories U.K. Ltd. The company has now clarified to the Exchange that Onyx Scientific Ltd. had a total income of UK 3.85 millions and EBIDTA of UK 0.65 millions (EBIDTA margin 17%) for its financial year ended March 31, 2011. The 100% share capital of its holding Company Onyx Research Chemicals Ltd. is acquired by the Company's wholly owned subsidiary Ipca Laboratories U.K. Ltd. for UK 4.60 millions.
Jul 2011